Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Bronte Capital Amalthea Fund John Hempton | “The manager argues that Novo Nordisk is being outcompeted by Eli Lilly, which has a more effective and better-marketed drug. Consequently, Novo's sales measured in Danish Kroner have begun to fall, indicating a broken growth thesis. The manager views the stock's return to its pre-Ozempic price as a reflection of these competitive realities.” | BEAR | Q1 2026 Mar 31, 2026 | View Pitch |
Protean Select Pontus Dackmo | “The fund avoided a major drawdown by choosing to sit out Novo Nordisk's highly-anticipated Cagrisema Phase III study readout, recognizing the risk of crowded positioning. Despite the trial's mixed result and subsequent stock drop, the manager remains constructive on Novo's long-term cash flow, valuation, and shareholder friendliness.” | BULL | Q4 2024 Jan 7, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
